Rev-Erb-a and Rev-Erb-b are nuclear receptors that regulate the expression of genes involved in the control of circadian rhythm 1,2 , metabolism 3,4 and inflammatory responses 5 . Rev-Erbs function as transcriptional repressors by recruiting nuclear receptor co-repressor (NCoR)-HDAC3 complexes to Rev-Erb response elements in enhancers and promoters of target genes 6-8 , but the molecular basis for cellspecific programs of repression is not known. Here we present evidence that in mouse macrophages Rev-Erbs regulate target gene expression by inhibiting the functions of distal enhancers that are selected by macrophage-lineage-determining factors, thereby establishing a macrophage-specific program of repression. Remarkably, the repressive functions of Rev-Erbs are associated with their ability to inhibit the transcription of enhancer-derived RNAs (eRNAs). Furthermore, targeted degradation of eRNAs at two enhancers subject to negative regulation by Rev-Erbs resulted in reduced expression of nearby messenger RNAs, suggesting a direct role of these eRNAs in enhancer function. By precisely defining eRNA start sites using a modified form of global run-on sequencing that quantifies nascent 59 ends, we show that transfer of full enhancer activity to a target promoter requires both the sequences mediating transcription-factor binding and the specific sequences encoding the eRNA transcript. These studies provide evidence for a direct role of eRNAs in contributing to enhancer functions and suggest that Rev-Erbs act to suppress gene expression at a distance by repressing eRNA transcription.
Rev-Erb-a and Rev-Erb-b are nuclear receptors that regulate the expression of genes involved in the control of circadian rhythm 1,2 , metabolism 3, 4 and inflammatory responses 5 . Rev-Erbs function as transcriptional repressors by recruiting nuclear receptor co-repressor (NCoR)-HDAC3 complexes to Rev-Erb response elements in enhancers and promoters of target genes [6] [7] [8] , but the molecular basis for cellspecific programs of repression is not known. Here we present evidence that in mouse macrophages Rev-Erbs regulate target gene expression by inhibiting the functions of distal enhancers that are selected by macrophage-lineage-determining factors, thereby establishing a macrophage-specific program of repression. Remarkably, the repressive functions of Rev-Erbs are associated with their ability to inhibit the transcription of enhancer-derived RNAs (eRNAs). Furthermore, targeted degradation of eRNAs at two enhancers subject to negative regulation by Rev-Erbs resulted in reduced expression of nearby messenger RNAs, suggesting a direct role of these eRNAs in enhancer function. By precisely defining eRNA start sites using a modified form of global run-on sequencing that quantifies nascent 59 ends, we show that transfer of full enhancer activity to a target promoter requires both the sequences mediating transcription-factor binding and the specific sequences encoding the eRNA transcript. These studies provide evidence for a direct role of eRNAs in contributing to enhancer functions and suggest that Rev-Erbs act to suppress gene expression at a distance by repressing eRNA transcription.
To study the mechanisms underlying Rev-Erb regulation of macrophage gene expression, we first determined genome-wide binding profiles in mouse RAW264.7 macrophages engineered to contain biotin-tagged Rev-Erb-a and Rev-Erb-b. Chromatin immunoprecipitation linked to deep sequencing (ChIP-Seq) indicated enrichment for both Rev-Erb-a and Rev-Erb-b at the promoter of the circadian target gene Bmal1 (also known as Arntl) ( Supplementary Fig. 1a ), in accordance with previous studies 1, 7 . We focused on a core set of highest confidence peaks (n 5 1,544) occupied by both proteins for detailed analysis ( Fig. 1a and Supplementary Fig. 1b ). Most (,90%) Rev-Erb peaks were in intra-and intergenic regions at least 1 kilobase (kb) away from annotated transcription start sites (TSSs) ( Supplementary  Fig. 1c ), exemplified by binding sites vicinal to the Mmp9 and Cx3cr1 genes (Fig. 1b ). In addition, ,70% of Rev-Erb-bound sites were in regions demarcated by high H3K4me1 and low H3K4me3, a combination characteristic of enhancer elements 9 (Fig. 1a ). De novo motif discovery of Rev-Erb-bound loci returned significant enrichment for binding sites for Rev-Erb, PU.1, AP1 and C/EBP (Fig. 1c ). PU.1, AP1 and C/EBP transcription factors are required for macrophage differentiation 10 and have recently been shown to select the majority of the enhancer-like elements in macrophages 11 . Colocalization of Rev-Erbs with PU.1 and C/EBP in macrophages was confirmed by comparison with direct binding data for these factors 11 (Fig. 1a, b ). Consistent with these findings, most of the Rev-Erb-bound sites defined here localize to enhancer-like elements specific for macrophages ( Supplementary Fig. 2a, b) .
We next performed global run-on sequencing (GRO-seq) 12 in Rev-Erb-a/Rev-Erb-b-deficient and wild-type bone-marrow-derived macrophages (BMDMs) from Tie2-Cre; Rev-Erba flox/flox ; Rev-Erbb flox/flox (double knockout; DKO) animals and Cre-negative littermates (wild type). Tie2-Cre expression in haematopoietic stem cells 13 resulted in excision efficiencies in DKO macrophages of 85% for Rev-Erb-a and 92% for Rev-Erb-b ( Supplementary Fig. 3 ). GRO-seq analysis indicated that 142 mRNAs were significantly upregulated in DKO macrophages (P value ,0.005), and 71 genes were downregulated (P value ,0.005) ( Supplementary Table 1 ). Quantitative polymerase chain reaction with reverse transcription (qRT-PCR) confirmed upregulation of Mmp9 and Cx3cr1 mRNAs in Rev-Erb DKO macrophages ( Fig. 1d ). Conversely, constitutive expression of either Rev-Erb-a or Rev-Erb-b in RAW264.7 macrophages resulted in repression of Mmp9 and Cx3cr1 expression ( Fig. 1e and Supplementary Fig. 4a, b ). Analysis of multiple independent clones indicated that the extent of Mmp9 and Cx3cr1 repression correlated with Rev-Erb expression levels ( Supplementary Fig. 4c-f ). Genes that were upregulated in DKO macrophages were significantly closer to Rev-Erb-binding sites than downregulated genes ( Fig. 1f ), consistent with primary roles of Rev-Erbs as transcriptional repressors. However, only 3 of the 142 upregulated genes had Rev-Erb peaks within 2 kb of annotated TSSs, suggesting that Rev-Erbs primarily act to repress gene expression at distant enhancer-like elements.
We next tested genomic regions containing Rev-Erb-binding sites for enhancer activity. A 983 base pair (bp) region surrounding the Rev-Erb-bound site at 25 kb from the Mmp9 TSS was cloned downstream of a luciferase reporter driven by a TATA-like promoter ( Fig. 1g ). This region increased reporter gene activity in RAW264.7 macrophages and was sensitive to Rev-Erb repression (Fig. 1g ). By contrast, this element is inactive in a hepatoma cell line that lacks expression of PU.1 (Supplementary Fig. 5 ). RAR-related orphan nuclear receptors (RORs) also bind to Rev-Erb response elements and constitutively activate gene expression 14 . Consistent with this, we found that constitutive expression of ROR-a increased activity of the Mmp9 enhancer element ( Supplementary Fig. 6 ). Co-expression of wild-type Rev-Erb-b, but not Rev-Erb-b with a mutation disrupting sequence-specific DNA binding, antagonized ROR-a activation ( Supplementary Fig. 6 ). Six of six other Rev-Erb-bound distal regions chosen for analysis were activated by ROR-a, four of which were antagonized by Rev-Erb cotransfection.
Examination of GRO-seq data at intergenic Rev-Erb-binding sites exhibiting the enhancer histone signature H3K4me1 hi /H3K4me3 lo indicated the presence of bidirectional transcripts ( Fig. 2a-c) , consistent with recent studies indicating that RNAs are transcribed from distal enhancer elements on a genome-wide scale [15] [16] [17] . To determine whether transcripts were being initiated at enhancers, we modified the GRO-seq protocol to detect nascent RNA with a 59 7-methylguanylated cap (59-GRO-seq). This methodology precisely localized start sites of well-characterized mRNAs ( Supplementary Fig. 7 ) and identified eRNA initiation at 76% of the Rev-Erb-binding sites at enhancer-like regions of the genome (Fig. 2a ). Most (56%) of these sites direct bidirectional transcription, exemplified by the Mmp9 25 kb and Cx3cr1 28 kb enhancers ( Fig. 2b) . No significant GRO-seq signal was detected in macrophages at locations of intergenic Rev-Erb-a peaks in liver 8 (Fig. 2c ), consistent with cell-type-specific eRNA expression.
To determine whether Rev-Erbs regulate eRNA expression, transcription of nascent RNA at Rev-Erb-bound enhancers was examined in both loss-and gain-of-function models. Rev-Erb-b binding was strongly associated with a reduced 59-GRO-seq signal at the most confident Rev-Erb-b-binding sites ( Supplementary Fig. 8a ). Analysis of the averaged 59-GRO-seq signal at the top 100 Rev-Erb intergenic enhancers showed a marked decrease of eRNA initiation in macrophages overexpressing Rev-Erb-a compared with control macrophages (Fig. 2d ). Conversely, the GRO-seq RNA signal was increased overall in these same intergenic enhancers in Rev-Erb DKO macrophages ( Supplementary Fig. 9a ). In both loss-and gain-of-function experiments, the eRNA signal at the top 100 PU.1-bound enhancers showed no significant change (for example, Supplementary Fig. 9b ), indicating that changes in eRNA are specific to Rev-Erb-bound elements. The effects of gain or loss of Rev-Erb function on eRNA expression at the Mmp9 25 kb and Cx3cr1 28 kb enhancers were confirmed by RT-PCR ( Fig. 2e, f) . Overall, levels of de-repressed eRNAs in Rev-Erb DKO macrophages were inversely correlated to levels of eRNA repression upon constitutive expression of Rev-Erb-a ( Supplementary Fig. 8b ). 
RESEARCH LETTER
ChIP-Seq experiments demonstrated that gain or loss of Rev-Erb function also resulted in reciprocal loss or gain of H3K9 acetylation (H3K9ac) at Rev-Erb-occupied enhancers, respectively ( Fig. 1b and Supplementary Fig. 10a , c, e-g), consistent with Rev-Erb-mediated recruitment of NCoR-HDAC3 complexes 7 . By contrast, H3K9ac was not changed at the global set of PU.1 enhancers ( Supplementary  Fig. 10b, d) . Notably, constitutive expression of Rev-Erb-a had no significant effect on H3K4me1 or PU.1 binding at Rev-Erb-bound enhancer elements ( Supplementary Fig. 11a, b ), despite the profound changes in eRNA initiation ( Fig. 2b, d) .
Collectively, these results raised the possibility that Rev-Erbs repressed gene expression at a distance by regulating enhancer-directed transcription. Consistent with this possibility, changes in eRNA expression at Rev-Erb-bound sites due to gain or loss of Rev-Erb function were associated with changes in expression of the nearest mRNA (Supplementary Fig. 12a, b ), and were better predictors than Rev-Erb binding itself ( Supplementary Fig. 12c, d ). In addition, although levels of eRNAs are low at steady state 15 , 59-GRO-seq data suggest that the extent of engaged RNA polymerase II (RNAPII) at enhancers is often comparable to that at promoters, as exemplified by Cx3cr1 and Mmp9 (Fig. 2b) . Three experimental approaches were used to investigate whether the synthesis of enhancer-directed RNA transcripts contributed to enhancer activity. First, we designed short interfering RNAs (siRNAs) that specifically reduced expression of eRNAs associated with the Mmp9 or Cx3cr1 enhancers in primary wild-type macrophages. Reduced eRNA expression was associated with a corresponding reduction of Mmp9 and Cx3cr1 mRNAs, but not mRNAs from their nearest expressing genes, Ncoa5 and Csrnp1, respectively ( Fig. 3a, b ). Furthermore, these siRNAs reversed the de-repression phenotype associated with increased eRNA expression in Rev-Erb DKO macrophages. Importantly, the siRNA directed against the sense-strand Mmp9 eRNA had no effect on expression of the antisense-strand eRNA or binding of PU.1 to the Mmp9 25 kb enhancer (Supplementary Fig. 13 ), thereby excluding potential silencing effects of the siRNA on the transcriptional activity of the 25 kb enhancer itself.
As a second approach, we used antisense oligonucleotides (ASOs) to knock down Mmp9 25 kb and Cx3cr1 28 kb enhancer eRNAs. ASOs mediate nuclear RNA degradation via an RNaseH pathway 18 . This provides an independent method for eRNA targeting, as siRNA-directed silencing may alter enhancer function through ways other than RNA degradation 19, 20 . We systematically screened ASOs targeting the Mmp9 25 kb and Cx3cr1 28 kb eRNAs ( Supplementary Fig. 14) and selected subsets of the most effective ASOs for detailed analysis. ASOs with the ability to reduce Mmp9 25 kb sense-strand eRNA expression resulted in dose-dependent reduction of the corresponding Mmp9 mRNA, but did not affect the Cx3cr1 mRNA ( Fig. 3c ). ASOs with the ability to knock down the antisense-strand Cx3cr1 28 kb eRNA reduced Cx3cr1, but not Mmp9 or Csrnp1 expression ( Fig. 3d ).
As a third approach, we examined the functional significance of the Mmp9 and Cx3cr1 eRNAs using an enhancer assay guided by 59-GROseq definition of eRNA start sites. The 983 bp sequence upstream of Mmp9 that confers Rev-Erb-regulated enhancer activity in RAW264.7 cells encompasses a 388 bp central region containing the binding sites for PU.1, C/EBPs, AP-1 and Rev-Erbs, as well as start sites of senseand antisense-strand eRNAs (Fig. 4a) . Notably, the 388 bp core was significantly less active than the 983 bp sequence, which encodes the eRNAs (Fig. 4b) . Expression of the sense-strand eRNA from the 983 bp enhancer was confirmed by RT-PCR using a reporter-specific primer for first-strand complementary DNA synthesis ( Fig. 4c ). Addition of DNA encoding the sense-strand eRNA, but not the antisense-strand eRNA, restored transcriptional activity to the 388 bp core ( Fig. 4d) , consistent with the finding that siRNAs and ASOs directed against the sense-strand eRNA resulted in reduction of Mmp9 mRNA expression. A similar activity of the sense-strand eRNA was observed when the 983 bp or core enhancer elements were inserted in the reverse orientation ( Supplementary Fig. 15 ). Similarly, the central 210 bp of the Cx3cr1 28 kb enhancer containing PU.1-and Rev-Erb-binding sites was less active than a 967 bp fragment encoding sense-and antisense-strand eRNAs. Adding back the antisense-strand eRNA, but not the sensestrand eRNA, restored the activity of the enhancer core ( Supplementary  Fig. 16 ), consistent with the results of the siRNA and ASO experiments.
We next reversed the orientation of the eRNA-coding sequences relative to the enhancer cores, thereby retaining any putative transcriptionfactor-binding sites but completely changing the sequence of any LETTER RESEARCH potential eRNA product. In the 'flipped' Mmp9 plus eRNA construct, Mmp9 enhancer activity was reduced to a level comparable to the 388 bp core (Fig. 4d) , despite production of a 'flipped' eRNA ( Fig. 4c and Supplementary Fig. 15 ). Corresponding results were obtained for the Cx3cr1 enhancer ( Supplementary Fig. 16 ).
As even broadly expressed genes are often under the control of cellspecific enhancers, these findings raised the question of whether enhancers might be considered as targets for cell-specific manipulation of gene expression in vivo. To explore this possibility, we induced sterile peritonitis in mice and investigated the ability of siRNAs directed against the Mmp9 25 kb sense-strand eRNA to alter Mmp9 mRNA expression. Using lipofectamine-siRNA delivery 21 , the eRNA-specific siRNA, but not a control siRNA, reduced expression of the 25 kb sense-strand eRNA and the Mmp9 primary transcript, as was observed in in vitro (Fig. 4e) .
We provide evidence that Rev-Erbs function to repress macrophage gene expression by repressing transcription from enhancers that are selected by macrophage-lineage-determining factors. The recent finding of widespread enhancer transcription raises the question of whether eRNAs represent 'noise' due to spurious transcription from regions of open chromatin, reflect an important role of enhancer transcription itself, or directly contribute to enhancer function. Our findings suggest that at least some eRNAs make a quantitative contribution to enhancer function, in agreement with findings for noncoding RNAs expressed in the vicinity of the p53 and SNAI1 genes 22, 23 . These results do not exclude transcription-independent functions of the enhancer core or roles of enhancer transcription unrelated to the eRNA product. A major goal for the future will be to establish the functional relevance of eRNAs in vivo. As the expression of many widely transcribed genes seems to be controlled by cell-restricted enhancers, the expression of such genes might be altered in a cell-restricted manner by targeting corresponding functional eRNAs. Recent advances in the development of chemically modified ASOs that can effectively reduce RNA expression in vivo 24 could potentially enable this effort, suggesting the possibility of an 'enhancer therapy' approach to the treatment of disease.
METHODS SUMMARY
BMDMs and thioglycollate-elicited macrophages (ThioMac) were generated from 4-6-week-old Rev-Erba flox/flox ; Rev-Erbb flox/flox mice with or without Tie2-Cre as previously described 21 . Rev-Erb-a and Rev-Erb-b were tagged with BLRP for in vivo biotinylation in RAW264.7 macrophages expressing Escherichia coli biotin ligase 11 . Biotin-based or antibody-based ChIP-Seq were performed as described 11 . Preparation for GRO and library sequencing was performed as described previously 16 . 59-GRO-seq was performed using modifications of the GRO-seq protocol enabling specific amplification of the 59 ends of capped transcripts. Identification and quantitation of ChIP-Seq peaks, GRO-seq and 59-GRO-seq transcripts and de novo transcription factor motif discovery were performed using HOMER (http:// biowhat.ucsd.edu/homer) 11, 16 . For expression analysis, RNA was harvested from macrophages using RNEasy kit (Qiagen), treated with Turbo-DNases (Ambion) and reverse transcribed using SuperScript III Reverse-Transcriptase (Invitrogen) with random hexamers. Values determined for mRNA or eRNA, using qPCR, are normalized to 36B4 mRNA content from at least three independent experiments in triplicates. For RNA interference (RNAi) experiments, non-targeting siRNA oligonucleotides or siRNA directed against Mmp9 and Cx3cr1 eRNA (Dharmacon) were transfected using DeliverX (Affymetrix) or Lipofectamine 2000 (Invitrogen) into ThioMac or BMDMs, respectively. For ASO experiments, non-target ASO (ASO control, Isis Pharmaceuticals no. 129700) or Mmp9-directed ASO (Mmp9 eRNA1, Isis no. 566237; Mmp9 eRNA2, Isis no. 566241) were transfected into ThioMac using Cytofectin (Gene Therapy System). Rev-Erb-bound enhancers were cloned into pGL4-based reporter and tested in RAW264.7 macrophages as described 11 . Thioglycollate-elicited sterile peritonitis and in vivo RNAi experiments were performed as described 21 . 
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METHODS
Reagents and expression plasmids. Rabbit anti-PU.1 (SC-352) was from Santa Cruz Biotechnology. Rabbit anti-H3K4me1 (8895) was purchased from Abcam. Rabbit anti-H3K9ac (07-352) was purchased from Millipore. Expression constructs for Rev-Erb-a (amino acid 1-614), Rev-Erb-b (amino acid 1-576) and ROR-a (amino acid 1-460) were cloned into p33Flag-CMV7.1 (Sigma) at NotI and BamHI sites. The following primers were used. Rev-Erb-a: 59-AGCTTGCGGCCGCTAT GACGACCCTGGACTCC-39, 59-ATTACGGATCCTCACTGGGCGTCCACC CG-39; Rev-Erb-b: 59-AGCTTGCGGCCGCTATGGAGCTGAACGCAGGA-39, 59-ATTACGGATCCTTAAGGATGAACTTTAA-39; ROR-a: 59-AGCTTGCG GCCGCTATGAAAGCTCAAATTGAA-39, 59-ACCCGGGATCCTTACCCAT CGATTTGCATG-39. Mutation of the DNA-binding domain of Rev-Erb-b was generated using QuickChange II site-directed mutagenesis (Stratagene). The cysteines in the zinc finger domain (Rev-Erb-b, amino acid 133 and 136) were mutated to alanines using the following oligonucleotides, with mutated sequence in bold: Rev-Erb-b sense: 59-AGTGGCATGGTTCTACTGGCTAAAGTCGCTG GGGATGTGGCATCAGG-39; antisense: 59-CCTGATGCCACATCCCCAGCG ACTTTAGCCAGTAGAACCATGCCACT-39. Rev-Erb DKO mice and genotyping. Mice with floxed alleles for Rev-Erb-a and Rev-Erb-b were prepared as described 25 . Rev-Erba flox/flox ; Rev-Erbb flox/flox mice were crossed with Tie2-Cre; Rev-Erba flox/flox ; Rev-Erbb flox/flox mice to obtain haematopoietic-specific knockout of Rev-Erbs. Littermates without the Tie2-Cre transgene were used as controls. DNA was harvested from mouse tails or from macrophages, and standard PCR protocol was used for genotyping. The Tie2-Cre transgene was detected using primers 59-GCATTACCGGTCGATGCAACGAGT GATGAG-39 and 59-GAGTGAACGAACCTGGTCGAAATCAGTGCG-39, yielding a 408 bp PCR product. Genotyping PCR primers 59-TCTCCGTTGGCATGTCT AGAGATGG-39 and 59-GAAGAGTGTGTGTTTGCCCAAGAGG-39 were used to distinguish wild-type (191 bp) and floxed (332 bp) alleles in the Rev-Erba locus. Genotyping PCR primers 59-GGTTAGGTTTGTGAGTGTCCACAGC-39 and 59-AAGTGCTCCAACAAGGTAGTGCA-39 were used to distinguish wild-type (236 bp) and floxed (377 bp) alleles in the Rev-Erbb locus. Generation of biotin-tagged Rev-Erb-a and Rev-Erb-b. Details on generating biotin-tagged proteins stably expressed in RAW264.7 macrophages were previously published 11 . Briefly, Rev-Erbs were fused in-frame at the N terminus with amino acid peptide MAGGLNDIFEAQKIEWHEDTGGGGSGGGGSGENLYFQS containing a BLRP and a TEV-protease-specific cleavage sequence (in bold). BLRPempty, BLRP-Rev-Erb-a or BLRP-Rev-Erb-b expression plasmid was transfected into RAW264.7 macrophages engineered to stably express BirA. G418 (275 ng ml 21 ) and puromycin (2.5 mg ml 21 ) were used for stable selection. Multiple stable cell lines were isolated and screened for BLRP-Rev-Erb expression and biotinylation by western blot using anti Avi-tag antibody specifically recognizing the BLRP tag (Genscript) or HRP-streptavidin (Jackson Immunoresearch), respectively.
The following primers were used for cloning full-length Rev-Erb-a and Rev-Erb-b at the NotI/PmelI sites in the BLRP expression constructs. BLRP-Rev-Erb-a, AGCTTGCGGCCGCTATGACGACCCTGGACTCC, AGCTTTGTTTAAACT CACTGGGCGTCCACCCG; BLRP-Rev-Erb-b, AGCTTGCGGCCGCTATGG AGCTGAACGCAGGA, AGCTTTGTTTAAACTTAAGGATGAACTTTAA. ChIP-Seq. Detailed protocols for antibody-based ChIP experiments were previously described 11 . ChIP for biotinylated Rev-Erbs was performed as described 11 with the following modifications. Sonicated chromatin was incubated with BSA-blocked streptavidin T1 Dynabeads (Invitrogen) overnight at 4 uC with rotation. The captured biotin-streptavidin complexes were washed, and samples were equilibrated in TEV buffer (50 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1% NP-40 (CA630), 0.5 mM EDTA) for 5 min at room temperature (25 uC), followed by AcTEV protease (Invitrogen) digestion (5-10 U) for 1 h at room temperature in 40 ml TEV buffer. The streptavidin-conjugated beads were eluted again with TEV buffer with 10 min incubation at room temperature. Eluted samples were reverse cross-linked and RNaseA-and proteinase-K-treated following a standard ChIP protocol 11 . ChIP fragments were ligated to Genomic adaptor (Illumina) or NEXTflex DNA barcode adaptors (BioO Scientific). Adaptor ligated DNA fragments were size selected (150-250 bp), PCR amplified and sequenced on the Illumina Genome Analyzer or HiSeq system according to the manufacturer's instructions. ChIP-Seq analysis and de novo motif discovery. ChIP-Seq peak identification, quality control, and motif analysis were performed using HOMER (http://biowhat. ucsd.edu/homer) as described 11, 16 . Peaks from separate experiments were considered co-bound if their peak centres were located within 200 bp of each other. For de novo motif analysis, transcription factor motif finding was performed on 6100 bp relative to the peak centre defined from ChIP-Seq. Peak sequences were compared to random genomic fragments of the same size and normalized G1C content to identify motifs enriched in the ChIP-Seq targeted sequence. To generate histograms for the average distribution of tag densities, position-corrected, normalized tags in 40 bp windows were tabulated within the indicated distance from specific sites in the genome (that is, Rev-Erb-binding sites). Clustering plots for normalized tag densities at each genomic region were generated using HOMER and then clustered using Cluster (http://bonsai.hgc.jp/,mdehoon/software/cluster/) and visualized using Java TreeView 26 . GRO-seq. GRO and library preparation for sequencing was described previously 16 . Four 10-cm plates of confluent BMDMs from wild-type control or Rev-Erb DKO were used as the starting material. Two biological samples were used per group. Approximately 10 million nuclei per sample were extracted and used for run-on and BrU incorporation. BrU-labelled nascent transcripts were immunoprecipiated with anti-BrdU agarose beads (Santa Cruz Biotech), washed, eluted and precipitated in ethanol.
BrU-precipitated RNA was subjected to first-strand cDNA synthesis. First, polyA tails were added using Poly(A)-polymerase (NEB). Reverse transcription was then performed using Scriptscript III Reverse Transcriptase (Invitrogen) with oNTI223 primer (59-pGATCGTCGGACTGTAGAACTCT; CAAGCAGAAGA CGGCATACGATTTTTTTTTTTTTTTTTTTTVN-39) where the p indicates 59 phosphorylation, the semi-colon indicates the abasic dSpacer furan, and VN indicates degenerate nucleotides. Subsequently, excess oNTI223 primers were removed by Exonuclease I (Fermentas). First-strand cDNA products were fragmented with basic hydrolysis and size selected (105-400 nucleotides) in a 10% polyacrylamide TBE-urea gel (Invitrogen).
cDNA was subsequently circularized using CircLigase (Epicentre), and relinearized at the basic dSpacer furan with ApeI (NEB). The single-stranded DNA (ssDNA) template was amplified to generate DNA for sequencing by Phusion Hig-Fidelity DNA Polymerase (Thermo Science) with primers oNTI200 (59-CAAGCAGAAGACGGCATA-39) and oNTI201 (59-AATG ATACGGCGACCA CCGACAGGTTCAGAGTTCTACAGTCCGACG-39). PCR product was purified and size selected (140-225 bp) by gel electrophoresis on a non-denaturing 8% polyacrylamide TBE gel (Invitrogen). Purified DNA was then sequenced on Illumina Genome Analyzer II according to the manufacturer's instructions with the small RNA sequencing primer 59-CGACAGGTTCAGAGTTCTACAGTCC GACGATC-39. 59-GRO-seq. Reactions were stopped and RNA was extracted with 450 ml Trizol LS reagent (Invitrogen), both according to the manufacturer's instructions. Following DNase treatment, the RNA was hydrolysed in 20 ml total volume with 2 ml RNA fragmentation buffer (Ambion) for 10 min, and divalent cations were removed by gel filtration. Fragmented RNA was then 39-dephosphorylated with polynucleotide kinase (Enzymatics) for 2 h at 37 uC. The reaction was stopped with EDTA, and PNK was inactivated and RNA denatured by heating the reaction to 75 uC for 5 min, then cooled on ice for 2 min. BrU-containing RNA fragments were precipitated using anti-BrdU agarose beads. The resulting RNA was dephosphorylated with calf intestinal phosphatase (NEB) and 59-de-capped with tobacco acid pyrophosphatase (Epicentre). The reaction was stopped and RNA was extracted with Trizol LS, and libraries were prepared by ligating Illumina TruSeq-compatible adapters to the RNA 39 and 59 ends with truncated mutant RNA ligase 2 (K227Q) and RNA ligase 1 (NEB), respectively, followed by reverse transcription, cDNA isolation and PCR amplification for 12 cycles. Final libraries were size selected on PAGE/TBE gels to 60-110 bp insert size. A detailed protocol is available on request. Genome-wide gene expression analysis with GRO-seq. GRO-seq analysis of genome-wide gene expression was performed by HOMER followed by edgeR 27 . Briefly, HOMER was used to generate a gene expression matrix by identifying uniquely mapped RNA tags to gene bodies based on RefSeq annotation for the mouse genome (mm9). Statistical analysis for differential expression was performed using edgeR 27 on raw sequencing reads from wild-type and Rev-Erb DKO macrophages with two biological replicates per group. Genes with P , 0.005 were considered as differentially expressed. Enhancer-associated RNA analysis. To examine regulation of eRNA expression, putative enhancers sites were first defined based on ChIP-Seq enrichment of H3K4me1 and H3K4me3 flanking 61,000 bp from the centre of the transcription factor of interest. Putative enhancers were defined by the following criteria: (1) regions were at least 2 kb away from annotated TSSs; (2) regions had at least 16 tags from H3K4me1 ChIP-Seq normalized to 10 million tags; and (3) normalized ChIP-Seq tag count for H3K4me1 was greater than H3K4me3. HOMER was used to quantify eRNA expression by tabulating normalized GRO-seq tags within 6800 bp from the centre of Rev-Erb-or PU.1-bound intergenic enhancers. For 59-GRO-seq experiments, tag counts within 6250 bp of enhancers were tabulated. Histograms of RNA distribution at indicated enhancers were generated by tabulating average normalized RNA tag counts at a resolution of 40 bp within 2 kb from centres of specified genomic sites (for example, Rev-Erb enhancers). Only enhancers with .4 tags from GRO-seq or 59-GRO-seq within the specified window were included in the expression analysis.
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Analysis of correlations between eRNAs and nearby protein-coding genes was performed by examining differential expression of eRNAs to that of the nearest expressing protein-coding genes. Briefly, Rev-Erb-bound enhancers were assigned to the nearest expressing annotated genes defined by having at least 20 sequencing tags normalized to the length of the gene body. Differential expression of eRNA was determined by GRO-seq from Rev-Erb DKO macrophages versus wild-type control, or by 59-GRO-seq from Rev-Erb-a-overexpressing macrophages to control. Differential expression of annotated protein-coding genes was determined by GRO-seq in Rev-Erb DKO experiments. The data set was categorized as 'up', 'no change' and 'down' on the basis of the differential expression of the eRNA. For Rev-Erb DKO GRO-seq, eRNA with a .1.5-fold change in GRO-seq signal was considered to be differentially expressed; for the Rev-Erb-a overexpression experiment, a 2-fold cut-off in 59-GRO-seq signal was used. Spearmen rank correlation was used to test whether changes in eRNA and the corresponding proteincoding gene co-varied. Construction of enhancer reporters. For construction of Rev-Erb enhancer reporter plasmids, 900-1,100 bp of sequence centred on Rev-Erb-bound sites flanked by demarcation of H3K4me1 were PCR amplified and cloned into pGL4-TATA-TK at the BamHI/SalI sites downstream of the luciferase reporter gene as previously described 11 . The following primers were used to PCR-amplify enhancer sequences from mouse genomic DNA. Arhgap25 33 kb enhancer: 59-GATCGTCGACTTTCCATGGGTCCAGAGATG-39; 59-GATCGGATCCAGC AGGCTGGGATATGAGTG-39. For experiments testing the functional significance of the eRNA-coding sequences for Mmp9 and Cx3cr1, various alterations of the enhancers were cloned into the BamHI/SalI site downstream of the luciferase gene in the pGL4 reporter driven by the Mmp9 and Cx3cr1 promoter, respectively. Inversion of the eRNAcoding sequence relative to the core element of Mmp9 (388 bp) and Cx3cr1 (210 bp) was achieved by Flip-PCR 28 , a two-step overlap extension method modified from PCR site-specific mutagenesis. Briefly, the first amplification step consisted of two reactions using two pairs of flanking and internal primers to generate two fragments of the wild type sequence. The internal primers comprised the inversion site where the 3' end anneals to their respective targets and the 5' overhang is complementary to the opposing PCR fragment. The two internal primers are also complementary, allowing the two PCR fragments to anneal in an inverted fashion and to extend and amplify with flanking primers in the second step.
The following primers were used for constructing each enhancer variants.
